XRAY Q3 2026 deep dive: revenue shortfall and guidance cut amid dental market headwinds
XRAY reported Q3 2026 revenue of $836M, missing estimates by 2.7%, with adjusted EPS of $0.29, missing by 6.2%. The company cut full-year revenue guidance to $3.5B and adjusted EPS to $1.25. Growth in Wellspect Healthcare and U.S. dental segments was offset by inventory reductions and market challenges in EMEA and the Middle East. Management highlighted cost-saving initiatives and investments in sales and education.
How this was made

The 30-second read
Why it matters
The earnings miss and guidance cut are likely to drive the stock lower in the short term.
Market read
First report of XRAY's earnings and guidance cut, a material corporate event for traders.
What to watch
One-time $39M gross profit benefit and ongoing cost‑saving initiatives may mitigate near‑term losses.
Background
XRAY reported Q3 2026 results with a revenue miss and lowered full-year guidance amid dental market headwinds.
Ticker impact
Q3 2026 results show revenue miss and lowered full-year guidance, a material earnings update.
downward pressure as market prices in lower revenue and EPS outlook
Revenue fell short of estimates and full-year revenue and EPS guidance were reduced, prompting investors to reassess valuation.
Market effects
Dental equipment sector may see broader pressure as peers face similar market headwinds.
EMEA and Middle East sales challenges could affect regional healthcare equipment indices.
Guidance cut adds to cautious sentiment in global medical device markets.
Counterpoint
If the company successfully executes cost savings and leverages Wellspect growth, the stock could rebound.
Key entities
- companyXRAY
Dental equipment manufacturer reporting Q3 2026 earnings.




